Decision Diagnostics Corp (DECN)

[rawman]

NOTE 5 is mind-boggling! Simply stated, the DECN shareholders are paying the patent attorney a bundle for patents that CEO Keith Berman personally owns. Plus, one could easily speculate the DECN shareholders are paying Berman a licensing fee to allow DECN to use the patents/IP that these same shareholders paid to research and file. Not a bad gig for the CEO!

One now has to wonder if the Shasta patents/IP rights have been assigned to DECN or directly to Keith Berman. On this one I am "guessing" the answer is DECN, because any Berman patents would not (should not!!) be shown on the DECN Balance Sheet. The Balance Sheet shows a significant, albeit possibly contrived, amount associated with patents and IP.

BTW, when did Pharma Tech Solutions become a wholly-owned subsidiary of DECN? Keith Berman and probably Robert Jagunich owned Pharma Tech Solutions, prior it becoming part of DECN. What were the financial details underlying the acquisition of Pharma Tech Solutions? How much did the DECN shareholders pay Berman and Jagunich? What was the "contrived value" of Pharma Tech Solutions, when the acquisition was consummated? Did DECN ever disclose a pre-acquisition Pharma Tech financial statement?

THE DECN FINANCIAL BS SEEMS "PERVASIVE" AND THIS DESCRIPTION MIGHT BE TOO KIND!